medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Burden of Post-COVID-19 Syndrome and Implications for Healthcare Service Planning: A Population-based Cohort Study

Dominik Menges, MD MPH[1] *, Tala Ballouz, MD MPH[1] *, Alexia Anagnostopoulos, MD MPH[1], Hélène E Aschmann, PhD[1], Anja Domenghino, MD[1,2], Jan S Fehr, MD[1], Milo A Puhan, MD PhD[1]

[1] *Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Hirschengraben 84, CH-8001 Zurich, Switzerland*

[2] *Department of Visceral and Transplantation Surgery, University Hospital Zurich, University of Zurich, Rämistrasse 100, CH-8091 Zurich, Switzerland*

* These authors contributed equally to this work.

Corresponding author:

Milo A Puhan, MD, PhD

Epidemiology, Biostatistics and Prevention Institute (EBPI)

University of Zurich

Hirschengraben 84, CH-8001 Zurich, Switzerland

Phone: +41 44 634 46 10, Email: miloalan.puhan@uzh.ch

Keywords: COVID-19, SARS-CoV-2, Post-COVID-19 Syndrome, Long Covid, Cohort Study, Healthcare Planning, Public Health, Epidemiology

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract

Background: Longer-term consequences after SARS-CoV-2 infection are becoming an important burden to societies and healthcare systems. Data on post-COVID-19 syndrome in the general population are required for the timely planning of healthcare services and resources. The objective of this study was to assess the prevalence of impaired health status and physical and mental health symptoms among individuals at least six months after SARS-CoV-2 infection, and to characterize their healthcare utilization.

Methods: This population-based prospective cohort study (Zurich SARS-CoV-2 Cohort) enrolled 431 adults from the general population with polymerase chain reaction-confirmed SARS-CoV-2 infection reported to health authorities between 27 February 2020 and 05 August 2020 in the Canton of Zurich, Switzerland. We evaluated the proportion of individuals reporting not to have fully recovered since SARS-CoV-2 infection, and the proportion reporting fatigue (Fatigue Assessment Scale), dyspnea (mMRC dyspnea scale) or depression (DASS-21) at six to eight months after diagnosis. Furthermore, the proportion of individuals with at least one healthcare contact after their acute illness was evaluated. Multivariable logistic regression models were used to assess factors associated with these main outcomes.

Results: Symptoms were present in 385 (89%) participants at diagnosis and 81 (19%) were initially hospitalized. At six to eight months, 111 (26%) reported not having fully recovered. 233 (55%) participants reported symptoms of fatigue, 96 (25%) had at least grade 1 dyspnea, and 111 (26%) had DASS-21 scores indicating symptoms of depression. 170 (40%) participants reported at least one general practitioner visit related to COVID-19 after acute illness, and 10% (8/81) of initially hospitalized individuals were rehospitalized. Individuals that have not fully recovered or suffer from fatigue, dyspnea or depression were more likely to have further healthcare contacts. However, a third of individuals (37/111) that have not fully recovered did not seek further care.

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Conclusions: In this population-based study, a relevant proportion of participants suffered from longer-term consequences after SARS-CoV-2 infection. With millions infected across the world, our findings emphasize the need for the timely planning of resources and patient-centered services for post-COVID-19 care.

Registration: ISRCTN14990068

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Background

As of February 2021, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has resulted in more than 110 million infected cases and almost 2.5 million lives lost, at significant costs to healthcare systems and societies worldwide [1]. While initial public health responses focused on reducing the acute burden of coronavirus disease 2019 (COVID-19), a growing body of evidence indicates that SARS-CoV-2 infection can also result in longer-term physical and mental health consequences, which are of increasing concern for healthcare systems [2–4]. Such consequences lasting for longer than three months after infection are currently referred to as “post-COVID-19 syndrome” or “Long Covid” [4].

Few observational studies, predominantly conducted in patients hospitalized for acute COVID-19, have examined the persistence of symptoms and development of complications after SARS-CoV-2 infection beyond three months [5–7]. These studies reported that 33% up to 76% of infected individuals may experience persistent complaints for at least six months after acute illness [5]. Further studies in hospitalized patients found that up to 20% of patients had to be rehospitalized [8], and up to 80% may require follow-up in primary care within 2 months of hospital discharge [9]. However, current evidence shows that post-COVID-19 syndrome does not only occur in individuals with severe disease requiring hospitalization or in older individuals with comorbidities, but also in young and previously healthy individuals with mild disease [3, 7, 10, 11]. Data regarding the full burden of post-COVID-19 syndrome in the broader population of infected individuals is currently lacking. It is increasingly acknowledged that specific healthcare services and resources will be required to support the needs of individuals suffering from post-COVID-19 syndrome [2, 4, 12]. In response, several countries have started to set up specialized clinics [13, 14], and multiple patient support groups and networks for affected individuals have been formed to improve the general understanding of post-COVID-19 syndrome and identify needs for healthcare systems [12].

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

To successfully plan healthcare services and efficiently allocate public health resources, it is essential to determine the burden of longer-term consequences of SARS-CoV-2 infection and the needs of affected individuals. In this population-based study of SARS-CoV-2 infected individuals surveyed at least six months after diagnosis, we aimed to assess the longer-term physical and mental health impact of COVID-19 and the associated healthcare utilization. Thereby, we aimed to provide an evidence base for the planning of healthcare services for individuals suffering from post-COVID-19 syndrome.

Methods

Study design and participants

This study is based on data from participants of the Zurich SARS-CoV-2 Cohort study, a prospective, longitudinal cohort of polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infected individuals diagnosed between 27 February 2020 and 05 August 2020. We recruited study participants from within contact tracing at the Department of Health of the Canton of Zurich, Switzerland, based on mandatory laboratory reporting of all individuals diagnosed with SARS-CoV-2. We screened all SARS-CoV-2-positive individuals for whom contact information was available for eligibility. Eligibility criteria were being aged 18 years or older and able to follow study procedures, having sufficient knowledge of the German language, and residing in the Canton of Zurich. We enrolled participants into the study between 06 October 2020 and 26 January 2021, at a median of 7.2 months (range 5.9 to 10.3 months) after their diagnosis. The study protocol was approved by the responsible ethics committee of the Canton of Zurich. Informed consent was obtained from all participants.

Data sources and outcome measurement

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

After enrolment, participants completed an electronic baseline questionnaire including questions on socio-demographics, medical comorbidities and risk factors, details on their acute SARS-CoV-2 infection, current health status and symptoms, healthcare contacts since diagnosis, and health-related quality of life. All data was collected through the Research Electronic Data Capture (REDCap) survey system.

Acute COVID-19 was defined as symptoms, consequences and healthcare contacts within four weeks of diagnosis. To capture the longer-term effects of SARS-CoV-2 infection, we evaluated whether participants who were symptomatic in the acute phase had fully recovered compared to their normal health status before infection using a four-category scale (i.e., feeling “recovered and symptom free”, “better but not fully recovered”, “neither better nor worse”, or “worse”). We assessed the presence and type of any new or ongoing symptoms since the acute illness using a comprehensive list of symptoms. Additionally, we reviewed and coded comments in free text fields for further new or ongoing symptoms not captured by the preconceived questionnaire.

We evaluated the presence of fatigue using the Fatigue Assessment Scale (FAS), using a score of 22 or more as a threshold for determining the presence of relevant fatigue [15]. To assess longer-term respiratory complications, we administered the modified Medical Research Council (mMRC) dyspnea scale [16]. We assessed the presence and severity of depression, anxiety and stress symptoms using the 21-item Depression, Anxiety and Stress Scale (DASS-21). We calculated category scores as the sum of subscale item scores multiplied by two and assigned corresponding severity levels according to official user guidance [17, 18]. We evaluated health-related quality of life using the EQ-5D-5L instrument and visual analogue scale (EQ VAS) [19, 20]. We used the Dutch value set for calculating EQ-5D-5L index scores, as no value set or guidance on the most appropriate value set for Switzerland is available, and we judged the the population of the Netherlands to be relatively similar to the Swiss population.

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

We assessed healthcare service utilization by eliciting all healthcare contacts that participants have had since their acute illness. We asked participants about any general practitioner visits, medical hotline calls, and hospital admissions, as well as the main reason for each contact. To evaluate healthcare utilization specifically due to COVID-19, we restricted our analysis to healthcare contacts reported to be related to persistent or worsening symptoms, complications or new medical diagnoses related to COVID-19, or routine follow-up after COVID-19. In addition, we asked participants to report any medical conditions that have been newly diagnosed since their acute illness and whether the condition was evaluated as COVID-19-related by their physician or themselves.

Statistical analysis

We used descriptive statistics to analyze participant characteristics and outcomes of interest, and present results for the entire study population as well as stratified by age groups, sex, and hospitalization status.

We examined the data for missing values and report such where applicable. For responses to the FAS and DASS-21 instruments, we replaced missing data with the mean of the scores from the other available items. This was done for a maximum of two missing values for the FAS and for a maximum of one value for the DASS-21. We omitted FAS or DASS-21 responses with higher amounts of missing data from respective analyses. For the EQ-5D-5L, responses with invalid and missing data were omitted given the small amount of missing data (n=4). No imputation was applied for other missing data.

We assessed associations of potential predictors with the primary outcomes using univariable and multivariable logistic regression models. We based model selection on clinical and

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

epidemiological reasoning and the Akaike Information Criterion (AIC). We defined age group, sex and initial hospitalization as a priori covariables in the models based on the findings of other studies. We performed model selection separately for each outcome of interest by including variables that improved model fit based on AIC, with a difference of 2 points considered relevant. For the outcome of (non-)recovery, we restricted the analysis to initially symptomatic participants since the respective question was conditional on the presence of symptoms at time of infection. We report regression analysis results as odds ratios (OR) with corresponding 95% confidence interval (CI) and two-sided Wald-type statistical test. No p-value adjustment was applied. All analyses were performed using R version 4.0.2 [21].

In sensitivity analyses, we stratified results into time periods with limited testing (period before 25 June 2020, testing restricted to high-risk or severely symptomatic individuals) and increased testing (period after 25 June 2020, all symptomatic individuals could be tested). Additionally, we stratified results into time periods with limited and high public awareness of post-COVID-19 syndrome (period before and after 09 November 2020, when major Swiss news outlets started reporting about the syndrome). Last, we descriptively compared participants and nonparticipants for age, sex, presence of symptoms and hospitalization at infection to assess potential selection of participants.

Results

Study population

Between 27 February 2020 and 05 August 2020, 4639 individuals were diagnosed with SARS-CoV-2 in the Canton of Zurich (Figure 1). Contact information was available for 2209 individuals, among which 1309 were eligible and invited to participate in our study. 442 individuals agreed to participate (participation rate 34%) and 431 were included in this analysis.

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

The median age of participants was 47 years (IQR 33 to 58 years) and 50% were female (Table 1). At least one chronic comorbidity was reported by 147 (34%) participants. During acute infection, 385 (89%) participants were symptomatic, with a median of 6 (IQR 3 to 8) symptoms reported. Symptoms were described as mild to moderate in 221 (51%) and severe to very severe in 164 participants (38%). Most commonly reported symptoms were fatigue (64%), fever (63%), cough (50%) and loss of taste or smell (49%). 81 (19%) participants were hospitalized due to COVID-19 for a median duration of 7 days (IQR 4 to 15 days).

Recovery and longer-term symptoms

Overall, 111 (26%) participants reported that they had not fully recovered at six to eight months after SARS-CoV-2 infection (Table 2). A higher percentage of female participants and initially hospitalized individuals reported not having fully recovered compared to males and non-hospitalized individuals, respectively. In multivariable analyses among initially symptomatic participants, we found evidence that severe to very severe symptoms during acute illness and the presence of comorbidities were associated with non-recovery (Figure 2; Supplementary Material, Table S1). Furthermore, females were less likely to have recovered compared to males, while there was no evidence for an association of age or initial hospitalization with non-recovery.

Similarly, 106 (25%) participants reported new or ongoing symptoms, with a higher percentage in females compared to males (Table 2). Fatigue (12%), cough (10%), sore throat (9%) and headache (9%) were the most frequently reported symptoms. Taste and smell disturbances were reported by 21 (5%) and rash by 3 (1%) individuals. Among non-recovered participants, 51 (46%) also described experiencing new or ongoing symptoms. Meanwhile, 55 (52%) participants reporting such symptoms stated not having fully recovered. Overall, 166 (39%) participants reported either not having fully recovered or having new or ongoing symptoms.

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Fatigue

Among all participants, 233 (55%) participants having a score indicating fatigue, with a median FAS score of 22 (IQR 19 to 25) (Table 2). Younger individuals and female participants more frequently reported symptoms of fatigue compared to older age groups and males, respectively. In multivariable analyses, we found evidence that individuals aged 40 years or older were less likely to experience fatigue compared to 18-39 year-old participants (Figure 2; Supplementary Material, Table S2). However, we found no evidence for an association of sex, initial symptom severity or hospitalization with fatigue.

Dyspnea

A total of 96 (25%) participants reported to suffer from mMRC grade 1 dyspnea or higher (Table 2). We observed a higher percentage of grade ≥1 dyspnea among older age individuals, females, and initially hospitalized participants. In multivariable analyses, we found evidence for an association of grade ≥1 dyspnea with female sex, initial hospitalization and body mass index, but not for initial symptom severity or smoking status (Figure 2; Supplementary Material, Table S3).

Depression, anxiety and stress

Overall, 111 (26%) participants reported symptoms of depression, 135 (32%) reported symptoms of anxiety, and 68 (16%) reported symptoms of stress (Table 2). Higher proportions of participants reported depressive symptoms in older age groups and among females. Similar contrasts were observed for symptoms of anxiety. Meanwhile, younger participants and females more often reported stress symptoms compared to older individuals and males, respectively. In multivariable analyses, we only found lower education status and being unemployed to be associated with symptoms of depression (Figure 2; Supplementary Material, Table S4).

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Overlap of main outcomes and health-related quality of life

In total, 296 (69%) participants were categorized as non-recovered or experiencing fatigue, dyspnea or depression. Among these, 19 (6.4%) participants reported all four outcomes, while 130 (44%) suffered only from one of them (Supplementary Material, Figure S1). Most frequent combinations were fatigue and depression (n=94, 32%), fatigue and non-recovery (n=78, 26%), and fatigue and mMRC grade ≥1 dyspnea (n=68, 23%). Among all participants, 225 (53%) reported problems in at least one EQ-5D-5L dimension. Most frequently affected dimensions were pain/discomfort (n=151, 39%) and anxiety/depression (n=133, 31%) (Table 2).

Healthcare service utilization

A total of 170 (40%) participants reported having had at least one contact with the healthcare system for reasons related to COVID-19 (Table 3). Out of 81 initially hospitalized individuals, 8 (10%) were rehospitalized at least once due to persistent symptoms or COVID-19-related complications. 224 (52%) participants reported at least one general practitioner visit for any reason, and 150 (36%) had a general practitioner visit related to COVID-19. Among those, the median number of COVID-19-related general practitioner visits was 2 (IQR 1 to 3). Older and initially hospitalized individuals more frequently reported having seen a general practitioner. Additionally, 31 (7%) participants reported to have called a medical hotline for a reason related to COVID-19. Among non-recovered participants, 33% (37/111) did not report any further healthcare contacts (Supplementary Material, Table S5).

Since infection, 77 (18%) participants reported a new physician-diagnosed medical condition. 27 (35%) of these diagnoses were considered as related to COVID-19 by their physician (Table 3). Most frequently reported COVID-19-related conditions concerned the respiratory system (56%), followed by neuro-cognitive (30%), cardiovascular (11%), and skin disorders (11%). In

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

multivariable analyses, we found evidence for an association between healthcare use and initial hospitalization, having experienced severe to very severe symptoms, sex, and age ≥40 years (Figure 3; Supplementary Material, Table S6). Furthermore, not having fully recovered, grade ≥1 dyspnea, fatigue and symptoms of depression were associated with further healthcare contacts after acute COVID-19.

Discussion

Main findings

In this population-based cohort study, we found that one in four people had not fully recovered within six to eight months after SARS-CoV-2 infection. More than half of the participants in our study reported symptoms of fatigue. One fourth suffered from some degree of dyspnea or had symptoms of depression. Overall, more than two thirds had not recovered or experienced fatigue, dyspnea or depression at the time of follow-up, with only partial overlap between these outcomes. While not all of these outcomes are necessarily attributable to COVID-19, our study showed that an important proportion of infected individuals may develop post-COVID-19 syndrome and that a wide range of healthcare services may be required to support their needs.

Two fifths of study participants had at least one further healthcare contact related to COVID-19 after acute illness. 36% of participants reported further general practitioner visits, 7% calls to medical hotlines, and 10% of initially hospitalized participants were rehospitalized at least once for persistent symptoms or complications. Compared to recovered individuals, those not having fully recovered were more than three times more likely to have further healthcare contacts. These findings highlight the considerable long-term impact that COVID-19 may have both on affected individuals and healthcare systems worldwide.

Evidence in context

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

The NICE guidelines defined post-COVID-19 syndrome as signs and symptoms developing during or after COVID-19 and continuing for more than 12 weeks [4]. Various studies have described a wide range of physical, cognitive and psychological symptoms persisting up to three months in individuals recovering from COVID-19 [22–31]. Yet, only few studies have assessed the persistence of symptoms beyond three months after infection [5–7].

Compared to studies that enrolled patients who were hospitalized for acute COVID-19 [5, 6], we observed a lower percentage of individuals suffering from longer-term symptoms. While these differences could be partly due to older participant populations and the restriction to hospitalized patients in their studies, we still observed lower proportions of non-recovery and persistent symptoms among hospitalized patients and older individuals. Meanwhile, a longitudinal cohort including 91% of participants with mild disease found persistent symptoms in 33% of outpatients and 31% of hospitalized patients [7]. These observations are more comparable to our findings. While differences in study populations and outcome measurement are likely to strongly affect the comparability of studies on post-COVID-19 syndrome, a relatively high prevalence of fatigue, dyspnea or exercise intolerance, and psychological symptoms have consistently been noted across studies [5–7, 10, 11].

Only few studies so far have described the utilization of healthcare services after COVID-19 [8, 9, 32–34]. At two months, 9% to 20% of patients hospitalized for COVID-19 were found to require rehospitalization, with a higher risk in older individuals and those with comorbidities [8, 9, 32–34]. The observed rehospitalization rate in our study is broadly consistent with these estimates. One study found that 78% of hospitalized participants had seen a primary care physician after hospital discharge for any reason after 2 months [9]. In our study, 63% of hospitalized participants reported having had a general practitioner visit after hospital discharge. As noted above, differences in study populations likely affect the comparison of results across

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

studies. Further studies based on standardized assessments of health outcomes and symptom complexes will be necessary to capture the full spectrum of post-COVID-19 syndrome.

Implications for healthcare resource planning

The management and care of individuals with post-COVID-19 syndrome is likely to become a substantial burden for healthcare systems worldwide. In Switzerland, more than half a million individuals have been diagnosed with COVID-19 [35], and around 1.5 million are estimated to have been infected according to current seroprevalence studies [36]. Based on our estimates, a relevant number of individuals suffering from longer-term complications has to be expected, which will require some degree of support or healthcare services. In our study, we provide more detailed data on healthcare utilization incurring due to COVID-19. More than a third of infected individuals in our study needed an average of two further primary care consultations related to protracted symptoms or complications. Interestingly, we also observed that despite an increased likelihood of seeking care in those who have not returned to their normal health status, approximately one third of these participants did not report any further healthcare contact after their acute illness. This indicates that there may be a relevant need among previously infected individuals for additional services specialized in the care of people with post-COVID-19 syndrome. Our study provides important evidence for understanding the longer-term complications and burden of COVID-19 on healthcare systems and for planning public health resources and tailored services accordingly.

Limitations

By relying on official records of all diagnosed infections, our study provided a unique opportunity to evaluate post-COVID-19 syndrome in the general population, based on the full spectrum of disease severity. However, our study also has several limitations.

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

First, most participants included in this analysis were diagnosed with COVID-19 during the first pandemic wave in Switzerland. The capacity constraints in SARS-CoV-2-testing up to June 2020 may have selected for a population with a higher risk of experiencing severe disease. Furthermore, increased awareness of post-COVID-19 syndrome may have resulted in more frequent reporting of health issues by participants. However, sensitivity analyses stratified by time periods of limited and increased testing and limited and increased awareness of post-COVID-19 syndrome did not show a relevant difference between the respective time periods (Supplementary Material, Table S7).

Second, self-selection bias may have occurred if individuals who are more concerned with their health were more likely to participate. Compared to individuals not participating in our study, participants in our study were younger on average, and a lower proportion was hospitalized for COVID-19 (19% compared to 24% of nonparticipants) (Supplementary Material, Table S8).

Third, we did not have a baseline (pre-COVID-19) assessment of participants' physical and mental health. Thus, it is impossible to distinguish the effects of COVID-19 from pre-existing conditions. The interpretation of our findings regarding depression and anxiety is further limited by the psychological burden that the pandemic may impose in general [37, 38]. While we tried to compare our results with estimates from the general population, applicable comparison data was not available.

Last, we did not evaluate the use of specialized medical (e.g., psychological/psychiatric care) or diagnostic services in our assessment. Thus, the true extent of healthcare service utilization may be underestimated. The unavailability of targeted post-COVID-19 care programs in Switzerland at the time of enrolment may have led to an underestimation of the healthcare demand to be expected once such programs become available.

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Conclusion

Our population-based cohort study showed that a considerable proportion of SARS-CoV-2 infected individuals experience longer-term consequences and have a relevant demand for healthcare services. A wide range of services and patient-centered, integrative approaches will be required to support the recovery of these individuals. It is thus crucial to timely allocate resources and plan healthcare services to respond to the needs of those suffering from post-COVID-19 syndrome.

List of abbreviations

AIC	Akaike Information Criterion
CI	Confidence Interval
COVID-19	Coronavirus disease 2019
DASS-21	21-item Depression, Anxiety and Stress Scale
EQ-5D-5L	EuroQol 5-dimension 5-level
EQ VAS	EuroQol Visual Analogue Scale
FAS	Fatigue Assessment Scale
IQR	Interquartile range
mMRC	Modified Medical Research Council
OR	Odds Ratio
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Declarations

Ethical approval: The study was approved by the responsible ethics committee of the Canton of Zurich, Switzerland (Kantonale Ethik-Kommission Zürich; BASEC-Nr. 2020-01739). Informed consent was obtained from all participants.

Consent for publication: Not applicable.

Availability of data and materials: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Data requestors will need to sign a data access agreement.

Competing interests: The authors declare that they have no competing interests.

Funding: The Zurich SARS-CoV-2 Cohort study is part of the Corona Immunitas research program, coordinated by the Swiss School of Public Health (SSPH+) and funded through SSPH+ fundraising, including funding by the Swiss Federal Office of Public Health, the Cantons of Switzerland (Basel, Vaud and Zurich), private funders (ethical guidelines for funding stated by SSPH+ were respected) and institutional funds of the participating universities. Additional funding specific to this study was provided by the Department of Health of the Canton of Zurich and the University of Zurich Foundation. Study funders had no role in the study design, data collection, analysis, interpretation, or writing of this report.

Authors' contributions: DM, TB, HEA, JSF and MAP conceived and planned the Zurich SARS-CoV-2 Cohort study. DM, TB and MAP coordinated the Zurich SARS-CoV-2 Cohort study. TB, DM, AA, JSF and MAP designed this study. HEA implemented and coordinated the

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

recruitment of study participants. TB, DM, and AD contributed to the enrolment of study participants and data collection. TB and DM prepared the analytic datasets and performed the statistical analysis. TB, DM, AA, JSF and MAP contributed to the interpretation of findings. TB and DM drafted the first manuscript. All authors had access to the data in the study and accept responsibility to submit for publication. All authors critically revised the draft manuscript and read and approved the final manuscript. MAP had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Acknowledgements: We would like to thank the study administration staff and the staff of the Corona Center of the University of Zurich for their excellent work and dedication to this study. Furthermore, we thank the Department of Health of the Canton of Zurich for their support and collaboration in realizing the study. And last, we thank all the study participants for their valuable time and commitment to the Zurich SARS-CoV-2 Cohort.

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

References

1. World Health Organization (WHO). Coronavirus Disease (COVID-19) Situation Reports: Weekly Epidemiological Update 23 February 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed 25 Feb 2021.

2. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026.

3. National Institute for Health Research (NIHR). Living with Covid19. 2020. doi:10.3310/themedreview_41169.

4. National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2020. https://www.nice.org.uk/guidance/ng188. Accessed 19 Jan 2021.

5. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220–32.

6. Bellan M, Soddu D, Balbo PE, Baricich A, Zeppegno P, Avanzi GC, et al. Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge. JAMA Netw Open. 2021;4:e2036142.

7. Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw Open. 2021;4:e210830.

8. Donnelly JP, Wang XQ, Iwashyna TJ, Prescott HC. Readmission and Death After Initial Hospital Discharge Among Patients With COVID-19 in a Large Multihospital System. JAMA. 2021;325:304.

9. Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-Day Outcomes Among Patients Hospitalized With COVID-19. Ann Intern Med. 2020;M20-5661.

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

10. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact. medRxiv. 2020; 12.24.20248802.

11. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App. medRxiv. 2020; 10.19.20214494.

12. Norton A, Olliaro P, Sigfrid L, Carson G, Paparella G, Hastie C, et al. Long COVID: tackling a multifaceted condition requires a multidisciplinary approach. The Lancet Infectious Diseases. 2021;S1473-3099(21)00043-8.

13. National Health Service (NHS) England. Long COVID patients to get help at more than 60 clinics. https://www.england.nhs.uk/2020/12/long-covid-patients-to-get-help-at-more-than-60-clinics/. Accessed 25 Feb 2021.

14. Center for Disease Control and Prevention (CDC). Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention. 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html. Accessed 18 Mar 2020.

15. Michielsen HJ, De Vries J, Van Heck GL. Psychometric qualities of a brief self-rated fatigue measure: The Fatigue Assessment Scale. Journal of Psychosomatic Research. 2003;54:345–52.

16. Mahler DA, Wells CK. Evaluation of Clinical Methods for Rating Dyspnea. Chest. 1988;93:580–6.

17. Depression Anxiety Stress Scales (DASS). http://www2.psy.unsw.edu.au/dass/. Accessed 25 Feb 2021.

18. Lovibond SH, Lovibond PF, Psychology Foundation of Australia. Manual for the depression anxiety stress scales. Sydney, N.S.W.: Psychology Foundation of Australia; 1995.

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

19. Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–36.

20. Devlin N, Parkin D, Janssen B. An Introduction to EQ-5D Instruments and Their Applications. In: Devlin N, Parkin D, Janssen B, editors. Methods for Analysing and Reporting EQ-5D Data. Cham: Springer International Publishing; 2020. p. 1–22.

21. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. 2017. https://www. R-project.org/.

22. Carfì A, Bernabei R, Landi F, for the Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324:603.

23. Carvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, Bourbao-Tournois C, Laribi S, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021;27:258–63.

24. Garrigues E, Janvier P, Kherabi Y, Bot AL, Hamon A, Gouze H, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. Journal of Infection. 2020;81:e4–6.

25. Goërtz YMJ, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6:00542–2020.

26. Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. Journal of Medical Virology. 2021;93:1013–22.

27. Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, et al. 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2020;thoraxjnl-2020-215818.

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

28. Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8:130–40.

29. Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLOS ONE. 2020;15:e0240784.

30. Wong AW, Shah AS, Johnston JC, Carlsten C, Ryerson CJ. Patient-reported outcome measures after COVID-19: a prospective cohort study. Eur Respir J. 2020;56.

31. Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clinical Microbiology and Infection. 2021;27:89–95.

32. Bowles KH, McDonald M, Barrón Y, Kennedy E, O'Connor M, Mikkelsen M. Surviving COVID-19 After Hospital Discharge: Symptom, Functional, and Adverse Outcomes of Home Health Recipients. Ann Intern Med. 2020;M20-5206.

33. Lavery AM, Preston LE, Ko JY, Chevinsky JR, DeSisto CL, Pennington AF, et al. Characteristics of Hospitalized COVID-19 Patients Discharged and Experiencing Same-Hospital Readmission — United States, March–August 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1695–9.

34. McCarthy CP, Murphy S, Jones-O'Connor M, Olshan DS, Khambhati JR, Rehman S, et al. Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system. EClinicalMedicine. 2020;26:100504.

35. Swiss Federal Office of Public Health (FOPH). COVID-19 Switzerland: Coronavirus Dashboard. https://www.covid19.admin.ch/en/overview. Accessed 25 Feb 2021.

36. Stringhini S, Zaballa M-E, Perez-Saez J, Pullen N, de Mestral C, Picazio A, et al. Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak. Lancet Infect Dis. 2021;S1473-3099(21)00054-2.

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

37. Vindegaard N, Benros ME. COVID-19 pandemic and mental health consequences: Systematic review of the current evidence. Brain, Behavior, and Immunity. 2020;89:531–42.

38. Quervain D de, Aerni A, Amini E, Bentz D, Coynel D, Freytag V, et al. The Swiss Corona Stress Study: second pandemic wave, November 2020. doi:10.31219/osf.io/6cseh.

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Tables and Figures

Table 1: Characteristics of study participants enrolled in the Zurich SARS-CoV-2 Cohort study.

Variable	N=431
Age (years)	
Median (IQR)	47 (33 to 58)
Age group (years)	
18-39	164 (38.1%)
40-64	205 (47.6%)
≥65	62 (14.4%)
Sex	
Female	214 (49.7%)
Male	217 (50.3%)
Time since diagnosis (days)	
Median (IQR)	220 (181 to 232)
Initial symptom severity	
Asymptomatic	46 (10.7%)
Mild to moderate	221 (51.3%)
Severe to very severe	164 (38.1%)
Initial symptom count	
Median (IQR)	6 (3 to 8)
Missing	*1*
Initial symptom duration	
Median (IQR)	10 (6 to 20)
Missing	*8*
Hospitalization and ICU stay	
Non-hospitalized	350 (81.2%)
Hospitalized without ICU stay	71 (16.5%)
Hospitalized with ICU stay	10 (2.3%)
Intubation during ICU stay (N=10)	7 (70%)
Smoking status	
Non-smoker	245 (57.2%)
Ex-smoker	122 (28.5%)
Smoker	61 (14.3%)
Missing	*3*
Body mass index	
Median (IQR)	24.8 (22.2 to 27.5)
Missing	*8*
Comorbidities	
No comorbidity	283 (65.7%)
At least one comorbidity	147 (34.1%)
Missing	*1*
Education	
None or mandatory school	20 (4.7%)
Vocational training or specialized baccalaureate	186 (43.5%)
Higher technical school or college	106 (24.8%)
University	116 (27.1%)
Missing	*3*
Employment	
Employed	321 (75.4%)
Student	14 (3.3%)
Retired	62 (14.6%)
Unemployed or other	29 (6.8%)
Missing	*5*

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Income (CHF)	
<6'000	133 (32.8%)
6'000 - 12'000	156 (38.4%)
>12'000	117 (28.8%)
Missing	*25*

Legend: CHF = Swiss Francs, ICU = Intensive Care Unit, IQR = Interquartile Range.

Table 2: Relative health status, fatigue, dyspnea, mental health, and health-related quality of life in study participants at six to eight months after SARS-CoV-2 infection.

Variable	Age group			Sex		Hospitalization		
	18-39 years, N=164	**40-64 years**, N=205	**≥65 years**, N=62	**Female**, N=214	**Male**, N=217	**Non-hospitalized**, N=350	**Hospitalized**, N=81	**Overall**, N=431
Recovery								
Recovered to normal health status	133 (81.1%)	140 (68.3%)	47 (75.8%)	148 (69.2%)	172 (79.3%)	268 (76.6%)	52 (64.2%)	320 (74.2%)
Not recovered to normal health status	31 (18.9%)	65 (31.7%)	15 (24.2%)	66 (30.8%)	45 (20.7%)	82 (23.4%)	29 (35.8%)	111 (25.8%)
Self-reported symptoms								
No new or ongoing symptoms	120 (73.2%)	151 (73.7%)	54 (87.1%)	151 (70.6%)	174 (80.2%)	263 (75.1%)	62 (76.5%)	325 (75.4%)
Any new or ongoing symptoms	44 (26.8%)	54 (26.3%)	8 (12.9%)	63 (29.4%)	43 (19.8%)	87 (24.9%)	19 (23.5%)	106 (24.6%)
Recovery and symptoms								
Recovered and symptom-free	105 (64.0%)	116 (56.6%)	44 (71.0%)	114 (53.3%)	151 (69.6%)	221 (63.1%)	44 (54.3%)	265 (61.5%)
Not recovered or experiencing symptoms	59 (36.0%)	89 (43.4%)	18 (29.0%)	100 (46.7%)	66 (30.4%)	129 (36.9%)	37 (45.7%)	166 (38.5%)
Fatigue (measured by FAS)								
No fatigue	59 (36.0%)	100 (49.0%)	34 (58.6%)	86 (40.8%)	107 (49.8%)	154 (44.1%)	39 (50.6%)	193 (45.3%)
Fatigue	105 (64.0%)	104 (51.0%)	24 (41.4%)	125 (59.2%)	108 (50.2%)	195 (55.9%)	38 (49.4%)	233 (54.7%)
Missing	*0*	*1*	*4*	*3*	*2*	*1*	*4*	*5*
Dyspnea (measured by mMRC scale)								
mMRC grade 0	126 (82.4%)	139 (74.3%)	34 (61.8%)	139 (70.9%)	160 (80.4%)	259 (81.4%)	40 (51.9%)	299 (75.7%)
mMRC grade 1	25 (16.3%)	39 (20.9%)	17 (30.9%)	48 (24.5%)	33 (16.6%)	53 (16.7%)	28 (36.4%)	81 (20.5%)
mMRC grade ≥2	2 (1.3%)	9 (4.8%)	4 (7.3%)	9 (4.6%)	6 (3.0%)	6 (1.9%)	9 (11.7%)	15 (3.8%)
Missing	*11*	*18*	*7*	*18*	*18*	*32*	*4*	*36*
Depression (measured by DASS-21)								
No depression	123 (75.0%)	151 (74.0%)	43 (71.7%)	149 (70.6%)	168 (77.4%)	263 (75.4%)	54 (68.4%)	317 (74.1%)
Mild to moderate depression	33 (20.1%)	39 (19.1%)	13 (21.7%)	50 (23.7%)	35 (16.1%)	68 (19.5%)	17 (21.5%)	85 (19.9%)
Severe to very severe depression	8 (4.9%)	14 (6.9%)	4 (6.7%)	12 (5.7%)	14 (6.5%)	18 (5.2%)	8 (10.1%)	26 (6.1%)
Missing	*0*	*1*	*2*	*3*	*0*	*1*	*2*	*3*
Anxiety (measured by DASS-21)								
No anxiety	114 (69.5%)	136 (67.3%)	41 (68.3%)	125 (59.5%)	166 (76.9%)	246 (70.7%)	45 (57.7%)	291 (68.3%)
Mild to moderate anxiety	38 (23.2%)	47 (23.3%)	18 (30.0%)	64 (30.5%)	39 (18.1%)	82 (23.6%)	21 (26.9%)	103 (24.2%)
Severe to very severe anxiety	12 (7.3%)	19 (9.4%)	1 (1.7%)	21 (10.0%)	11 (5.1%)	20 (5.7%)	12 (15.4%)	32 (7.5%)
Missing	*0*	*3*	*2*	*4*	*1*	*2*	*3*	*5*

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Stress (measured by DASS-21)								
No stress	134 (82.2%)	169 (82.8%)	54 (93.1%)	169 (80.1%)	188 (87.9%)	293 (84.2%)	64 (83.1%)	357 (84.0%)
Mild to moderate stress	21 (12.9%)	26 (12.7%)	4 (6.9%)	33 (15.6%)	18 (8.4%)	43 (12.4%)	8 (10.4%)	51 (12.0%)
Severe to very severe stress	8 (4.9%)	9 (4.4%)	0 (0.0%)	9 (4.3%)	8 (3.7%)	12 (3.4%)	5 (6.5%)	17 (4.0%)
Missing	*1*	*1*	*4*	*3*	*3*	*2*	*4*	*6*
EQ-5D mobility								
No mobility problems	156 (95.1%)	180 (87.8%)	45 (75.0%)	188 (88.3%)	193 (89.4%)	324 (92.8%)	57 (71.2%)	381 (88.8%)
Mobility problems	8 (4.9%)	25 (12.2%)	15 (25.0%)	25 (11.7%)	23 (10.6%)	25 (7.2%)	23 (28.7%)	48 (11.2%)
Missing	*0*	*0*	*2*	*1*	*1*	*1*	*1*	*2*
EQ-5D self care								
No problems with self-care	164 (100.0%)	203 (99.0%)	61 (100.0%)	212 (99.5%)	216 (99.5%)	348 (99.4%)	80 (100.0%)	428 (99.5%)
Problems with self-care	0 (0.0%)	2 (1.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	2 (0.6%)	0 (0.0%)	2 (0.5%)
Missing	*0*	*0*	*1*	*1*	*0*	*0*	*1*	*1*
EQ-5D usual activities								
No problems during usual activities	146 (89.0%)	184 (89.8%)	55 (90.2%)	184 (86.4%)	201 (92.6%)	322 (92.0%)	63 (78.8%)	385 (89.5%)
Problems during usual activities	18 (11.0%)	21 (10.2%)	6 (9.8%)	29 (13.6%)	16 (7.4%)	28 (8.0%)	17 (21.2%)	45 (10.5%)
Missing	*0*	*0*	*1*	*1*	*0*	*0*	*1*	*1*
EQ-5D pain & discomfort								
No pain or discomfort present	124 (75.6%)	124 (61.1%)	29 (47.5%)	132 (62.3%)	145 (67.1%)	241 (69.3%)	36 (45.0%)	277 (64.7%)
Pain or discomfort present	40 (24.4%)	79 (38.9%)	32 (52.5%)	80 (37.7%)	71 (32.9%)	107 (30.7%)	44 (55.0%)	151 (35.3%)
Missing	*0*	*2*	*1*	*2*	*1*	*2*	*1*	*3*
EQ-5D anxiety & depression								
No anxiety or depression present	107 (65.2%)	144 (70.2%)	46 (75.4%)	131 (61.5%)	166 (76.5%)	241 (68.9%)	56 (70.0%)	297 (69.1%)
Anxiety or depression present	57 (34.8%)	61 (29.8%)	15 (24.6%)	82 (38.5%)	51 (23.5%)	109 (31.1%)	24 (30.0%)	133 (30.9%)
Missing	*0*	*0*	*1*	*1*	*0*	*0*	*1*	*1*
EQ-5D-5L index score								
Median (IQR)	1.00 (0.86 to 1.00)	0.89 (0.85 to 1.00)	0.89 (0.82 to 1.00)	0.89 (0.82 to 1.00)	1.00 (0.87 to 1.00)	1.00 (0.86 to 1.00)	0.88 (0.82 to 1.00)	0.89 (0.85 to 1.00)
Range	0.41 to 1.00	0.07 to 1.00	0.47 to 1.00	0.37 to 1.00	0.07 to 1.00	0.07 to 1.00	0.37 to 1.00	0.07 to 1.00
Missing	*0*	*2*	*2*	*2*	*2*	*3*	*1*	*4*
EQ VAS								
Median (IQR)	85 (80 to 90)	85 (77 to 90)	80 (70 to 88)	85 (77 to 90)	85 (79 to 90)	85 (80 to 90)	80 (70 to 89)	85 (77 to 90)
Range	20 to 100	25 to 100	24 to 95	20 to 100	24 to 100	25 to 100	20 to 97	20 to 100
Missing	*2*	*6*	*2*	*6*	*4*	*5*	*5*	*10*

Legend: DASS-21 = Depression, Anxiety and Stress Score (21 items), EQ = EuroQol, FAS = Fatigue Assessment Scale, IQR = Interquartile Range, mMRC = modified Medical Research Council, VAS = Visual Analogue Scale.

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Table 3: Healthcare use and complications at six to eight months after SARS-CoV-2 infection.

	Age group			Sex		Hospitalization		
Variable	**18-39 years**, N=164	**40-64 years**, N=205	**≥65 years**, N=62	**Female**, N=214	**Male**, N=217	**Non-hospitalized**, N=350	**Hospitalized**, N=81	**Overall**, N=431
GP visit related to COVID-19	33 (20.4%)	85 (42.7%)	32 (53.3%)	80 (38.5%)	70 (32.9%)	100 (29.2%)	50 (63.3%)	150 (35.6%)
Missing	*2*	*6*	*2*	*6*	*4*	*8*	*2*	*10*
Number of GP visits related to COVID-19 [a]								
1-2	22 (67%)	63 (75%)	21 (66%)	56 (71%)	50 (71%)	70 (71%)	36 (72%)	106 (71%)
3-5	10 (30%)	18 (21%)	8 (25%)	19 (24%)	17 (24%)	26 (26%)	10 (20%)	36 (24%)
≥6	1 (3%)	3 (4%)	3 (9%)	4 (5%)	3 (4%)	3 (3%)	4 (8%)	7 (5%)
Missing	*0*	*1*	*0*	*1*	*0*	*1*	*0*	*1*
Medical hotline contact related to COVID-19	16 (9.8%)	13 (6.3%)	2 (3.3%)	19 (8.9%)	12 (5.6%)	25 (7.2%)	6 (7.4%)	31 (7.2%)
Missing	*0*	*0*	*1*	*0*	*1*	*1*	*0*	*1*
Number of medical hotline contacts related to COVID-19 [a]								
1-2	14 (88%)	7 (70%)	2 (100%)	15 (88%)	8 (73%)	18 (78%)	5 (100%)	23 (82%)
3-5	2 (12%)	3 (30%)	0 (0%)	2 (12%)	3 (27%)	5 (22%)	0 (0%)	5 (18%)
≥6	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Missing	*0*	*3*	*0*	*2*	*1*	*2*	*1*	*3*
Rehospitalizations related to COVID-19 (N=81)	1 (10%)	3 (7%)	4 (14%)	4 (11%)	4 (10%)	-	8 (10%)	8 (10%)
Number of rehospitalizations related to COVID-19 [a]								
1	0 (0%)	3 (100%)	4 (100%)	3 (75%)	4 (100%)	-	7 (88%)	7 (88%)
2-3	1 (100%)	0 (0%)	0 (0%)	1 (25%)	0 (0%)	-	1 (12%)	1 (12%)
GP visit or rehospitalization related to COVID-19	34 (21.0%)	85 (42.7%)	33 (55.0%)	82 (39.4%)	70 (32.9%)	100 (29.2%)	52 (65.8%)	152 (36.1%)
Missing	*2*	*6*	*2*	*6*	*4*	*8*	*2*	*10*
Healthcare contact related to COVID-19	45 (27.8%)	92 (46.2%)	33 (55.0%)	94 (45.2%)	76 (35.7%)	116 (33.9%)	54 (68.4%)	170 (40.4%)
Missing	*2*	*6*	*2*	*6*	*4*	*8*	*2*	*10*
New medical diagnoses	12 (7.3%)	47 (22.9%)	18 (29.0%)	36 (16.8%)	41 (18.9%)	43 (12.3%)	34 (42.0%)	77 (17.9%)
Type of new medical diagnosis [b]								
COVID-19 related complication (medically evaluated)	2 (17%)	17 (36%)	8 (44%)	12 (33%)	15 (37%)	12 (28%)	15 (44%)	27 (35%)
COVID-19 related complication (self-evaluated)	3 (25%)	6 (13%)	2 (11%)	6 (17%)	5 (12%)	7 (16%)	4 (12%)	11 (14%)
Non COVID-19 related diagnosis or unclear	7 (58%)	24 (51%)	8 (44%)	18 (50%)	21 (51%)	24 (56%)	15 (44%)	39 (51%)

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Legend: DASS-21 = Depression, Anxiety and Stress Score (21 items), EQ = EuroQol, FAS = Fatigue Assessment Scale, GP = General Practitioner, IQR = Interquartile Range, mMRC = modified Medical Research Council, VAS = Visual Analogue Scale. [a] *percentage within each category of healthcare contact (general practitioner visit, medical hotline call, rehospitalisaion),* [b] *percentage among all medical diagnoses.*

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 1: Flow chart for the inclusion of SARS-CoV-2 infected individuals from the Canton of Zurich, diagnosed between 27 February 2020 and 05 August 2020.

Figure 2: Associations for non-recovery, fatigue, dyspnea and depression at six to eight months after SARS-CoV-2 infection.

Legend: Panel a shows associations for not having fully recovered among initially symptomatic participants from multivariable logistic regression models adjusted for age, sex, initial hospitalization, symptom severity and presence of comorbidities. Panel b demonstrates associations for presence of fatigue (based on Fatigue Assessment Scale) from models adjusted for age, sex, and initial hospitalization. Panel c displays associations for presence of dyspnea (mMRC grade ≥1) from models adjusted for age, sex, initial hospitalization, smoking status, respiratory comorbidity and body mass index. Panel d shows associations for presence of depressive symptoms (based on DASS-21) from models adjusted for age, sex, initial hospitalization and symptom severity.

Figure 3: Associations for healthcare service utilization at six to eight months after SARS-CoV-2 infection.

Legend: Figure 3 shows associations for having at least one further healthcare contact after initial COVID-19, based on multivariable logistic regression models adjusted for age, sex, initial hospitalization, and initial symptom severity.



medRxiv preprint doi: https://doi.org/10.1101/2021.02.27.21252572; this version posted March 24, 2021. The copyright holder for (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in p
It is made available under a CC-BY-NC-ND 4.0 International license.

a Non−Recovery

Variable	N	Odds Ratio (95% CI)
Age group (years)	385	
18−39		Ref.
40−64		1.59 (0.93 to 2.73)
65+		0.97 (0.41 to 2.20)
Sex	385	
Female		Ref.
Male		0.53 (0.33 to 0.85)
Time since diagnosis (days)	385	
		0.99 (0.99 to 1.00)
Initial symptom severity	385	
Mild to moderate		Ref.
Severe to very severe		2.05 (1.27 to 3.34)
Initial hospitalization	385	
No		Ref.
Yes		1.17 (0.63 to 2.16)
Initial ICU stay	385	
No		Ref.
Yes		0.55 (0.10 to 2.49)
Smoking status	382	
Non−smoker		Ref.
Ex−smoker		1.48 (0.87 to 2.52)
Smoker		1.61 (0.78 to 3.24)
Body mass index	379	
		1.04 (0.99 to 1.09)
Comorbidities	384	
No		Ref.
Yes		2.08 (1.24 to 3.50)



b Fatigue

Variable	N	Odds Ratio (95% CI)
Age group (years)	426	
18−39		Ref.
40−64		0.59 (0.39 to 0.91)
65+		0.41 (0.21 to 0.78)
Sex	426	
Female		Ref.
Male		0.72 (0.49 to 1.07)
Time since diagnosis (days)	426	
		1.00 (1.00 to 1.01)
Initial symptom severity	426	
Asymptomatic		Ref.
Mild to moderate		0.96 (0.50 to 1.83)
Severe to very severe		1.38 (0.69 to 2.73)
Initial hospitalization	426	
No		Ref.
Yes		1.00 (0.59 to 1.71)
Initial ICU stay	426	
No		Ref.
Yes		4.63 (1.02 to 32.88)
Smoking status	424	
Non−smoker		Ref.
Ex−smoker		1.58 (1.00 to 2.52)
Smoker		1.27 (0.71 to 2.31)
Body mass index	419	
		1.04 (1.00 to 1.09)
Comorbidities	426	
No		Ref.
Yes		1.27 (0.81 to 2.01)



c Dyspnea

Variable	N	Odds Ratio (95% CI)
Age group (years)	395	
18−39		Ref.
40−64		0.79 (0.41 to 1.49)
65+		0.90 (0.37 to 2.16)
Sex	395	
Female		Ref.
Male		0.45 (0.26 to 0.76)
Time since diagnosis (days)	395	
		1.00 (0.99 to 1.01)
Initial symptom severity	395	
Asymptomatic		Ref.
Mild to moderate		1.00 (0.40 to 2.73)
Severe to very severe		1.42 (0.57 to 3.87)
Initial hospitalization	395	
No		Ref.
Yes		4.17 (2.23 to 7.91)
Initial ICU stay	395	
No		Ref.
Yes		1.05 (0.22 to 5.31)
Smoking status	393	
Non−smoker		Ref.
Ex−smoker		1.66 (0.92 to 3.00)
Smoker		1.31 (0.57 to 2.85)
Body mass index	388	
		1.14 (1.08 to 1.20)
Respiratory condition	388	
No		Ref.
Yes		1.71 (0.70 to 4.01)
Comorbidities	395	
No		Ref.
Yes		2.71 (1.38 to 5.36)



d Depression

Variable	N	Odds Ratio (95% CI)
Age group (years)	428	
18−39		Ref.
40−64		0.97 (0.59 to 1.59)
65+		1.18 (0.56 to 2.42)
Sex	428	
Female		Ref.
Male		0.74 (0.47 to 1.15)
Time since diagnosis (days)	428	
		1.00 (0.99 to 1.00)
Initial symptom severity	428	
Asymptomatic		Ref.
Mild to moderate		0.85 (0.40 to 1.94)
Severe to very severe		2.05 (0.96 to 4.69)
Initial hospitalization	428	
No		Ref.
Yes		1.05 (0.57 to 1.89)
Initial ICU stay	428	
No		Ref.
Yes		0.47 (0.07 to 2.17)
Smoking status	426	
Non−smoker		Ref.
Ex−smoker		1.21 (0.72 to 2.01)
Smoker		1.71 (0.89 to 3.21)
Body mass index	421	
		1.02 (0.97 to 1.06)
Comorbidities	428	
No		Ref.
Yes		1.41 (0.84 to 2.34)
Education	426	
None or mandatory school		Ref.
Vocational training or specialized baccalaureate		0.31 (0.11 to 0.85)
Higher technical school or college		0.27 (0.09 to 0.79)
University		0.23 (0.08 to 0.65)
Employment	424	
Employed		Ref.
Student		0.60 (0.09 to 2.41)
Retired		1.89 (0.58 to 6.11)
Unemployed or other		2.53 (1.12 to 5.63)
Income	405	
<6'000 CHF		Ref.
6'000 − 12'000 CHF		1.05 (0.61 to 1.81)
>12'000 CHF		0.84 (0.45 to 1.55)



Healthcare use

Variable	N	Odds Ratio (95% CI)
Age group (years)	421	
18−39		Ref.
40−64		1.94 (1.22 to 3.10)
65+		2.23 (1.12 to 4.45)
Sex	421	
Female		Ref.
Male		0.62 (0.41 to 0.95)
Time since diagnosis (days)	421	
		1.00 (0.99 to 1.00)
Initial symptom severity	421	
Asymptomatic		Ref.
Mild to moderate		1.50 (0.72 to 3.34)
Severe to very severe		2.59 (1.21 to 5.87)
Initial hospitalization	421	
No		Ref.
Yes		2.94 (1.66 to 5.32)
Initial ICU stay	421	
No		Ref.
Yes		3.65 (0.61 to 70.08)
Recovery	421	
Recovered to normal health status		Ref.
Not recovered to normal health status		3.53 (2.14 to 5.86)
Fatigue	417	
No		Ref.
Yes		1.61 (1.04 to 2.50)
Dyspnea	417	
mMRC grade 0		Ref.
mMRC grade 1−4		2.35 (1.40 to 3.99)
Depression	419	
No		Ref.
Yes		2.13 (1.32 to 3.45)
Smoking status	418	
Non−smoker		Ref.
Ex−smoker		1.14 (0.70 to 1.84)
Smoker		1.16 (0.61 to 2.18)
Body mass index	413	
		0.99 (0.94 to 1.03)
Comorbidities	420	
No		Ref.
Yes		1.14 (0.70 to 1.84)